US 8912214
Use of Chk2 kinase inhibitors for cancer treatment
granted A61KA61K31/17A61K31/175
Quick answer
US patent 8912214 (Use of Chk2 kinase inhibitors for cancer treatment) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/17, A61K31/175, A61K31/4184, A61P